Welcome to the Current Issues section of the Journal of Emerging Research in Cancer Pharmacotherapy (JERCP). This page provides access to the most recent and previously published issues of the journal, featuring innovative research and clinical advancements in cancer pharmacotherapy.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Targeted Nanocarrier Systems for Enhancing Bioavailability of Tyrosine Kinase Inhibitors in Metastatic Lung Cancer
Vol.2(1); Pages:1-9. Published on March-2026
Abstract
The therapeutic efficacy of tyrosine kinase inhibitors (TKIs) in metastatic lung cancer is often limited by poor bioavailability and systemic toxicity. This study investigates the development of a targeted nanocarrier system designed to enhance the delivery and absorption of TKIs. Polymeric nanoparticles conjugated with tumor specific ligands were synthesized and evaluated for drug loading efficiency, release kinetics, and cellular uptake in vitro. In vivo studies were conducted using murine xenograft models to assess pharmacokinetics and therapeutic outcomes. Results demonstrated a significant improvement in drug bioavailability, with enhanced tumor localization and reduced off-target effects. The nanocarrier system exhibited controlled drug release and improved cytotoxic activity against cancer cells compared to conventional formulations. These findings suggest that ligand-targeted nanocarriers represent a promising strategy for optimizing TKI therapy in metastatic lung cancer, potentially leading to improved patient outcomes and reduced adverse effects.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Immunomodulatory Effects of Novel Small-Molecule Inhibitors in Triple Negative Breast Cancer
Vol.2(1); Pages:10-18. Published on March-2026
Abstract
Triple-negative breast cancer (TNBC) lacks targeted therapies due to the absence of hormone receptors, making it a challenging subtype to treat. This study explores the immunomodulatory potential of newly synthesized small-molecule inhibitors targeting immune checkpoint pathways. The compounds were evaluated for their ability to modulate T-cell activation and cytokine production in vitro, followed by efficacy testing in TNBC murine models. Results indicated a significant increase in immune cell infiltration and activation within tumor microenvironments. Additionally, treated groups exhibited reduced tumor progression and improved survival rates. Mechanistic studies revealed that the inhibitors effectively suppressed PD-L1 expression and enhanced cytotoxic T-cell responses. The findings highlight the potential of small-molecule immunomodulators as adjunct therapies in TNBC, offering a novel approach to overcoming immune evasion mechanisms and improving therapeutic efficacy.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Comparative Pharmacokinetics of Oral Versus Injectable Chemotherapeutic Agents in Colorectal Cancer Patients
Vol.2(1); Pages:19-27. Published on April-2026
Abstract
The route of administration plays a critical role in the pharmacokinetics and overall effectiveness of chemotherapeutic agents. This study compares the pharmacokinetic profiles of oral and injectable formulations in colorectal cancer patients. A cohort of 120 patients was divided into two groups receiving equivalent doses via oral and intravenous routes. Plasma drug concentrations were measured at predefined intervals to assess absorption, distribution, metabolism, and excretion parameters. The oral formulation demonstrated variable absorption rates but improved patient compliance, whereas injectable agents provided more consistent plasma levels. Notably, oral administration resulted in reduced peak toxicity, while maintaining therapeutic efficacy in most patients. The study underscores the importance of individualized treatment planning and suggests that oral chemotherapeutics may serve as a viable alternative in selected patient populations, balancing efficacy with quality of life considerations.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Role of Epigenetic Modulators in Overcoming Drug Resistance in Ovarian Cancer
Vol.2(1); Pages:28-37. Published on April-2026
Abstract
Drug resistance remains a significant obstacle in the treatment of ovarian cancer, often leading to relapse and poor prognosis. This study investigates the role of epigenetic modulators in reversing resistance mechanisms. Histone deacetylase inhibitors and DNA methyltransferase inhibitors were evaluated for their ability to restore drug sensitivity in resistant ovarian cancer cell lines. Gene expression profiling revealed reactivation of tumor suppressor genes and downregulation of resistance-associated pathways. Combination therapy with standard chemotherapeutics resulted in enhanced apoptosis and reduced cell viability. In vivo validation confirmed the restoration of drug responsiveness and improved therapeutic outcomes. These findings highlight the potential of epigenetic therapies as a complementary approach to conventional treatment, offering new avenues for overcoming resistance and improving patient survival in ovarian cancer.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Engineering Polymer-Based Implant Systems for Prolonged Drug Delivery in Glioblastoma Treatment
Vol.2(1); Pages:38-46. Published on April-2026
Abstract
Glioblastoma is an aggressive brain tumor with limited treatment options due to the blood-brain barrier and rapid tumor progression. This study focuses on the development of biodegradable polymer-based implants for localized and sustained drug delivery. The implants were engineered using biocompatible polymers capable of controlled degradation and drug release. In vitro studies demonstrated consistent release profiles over several weeks, while in vivo implantation in glioblastoma models showed significant tumor growth inhibition. The localized delivery minimized systemic toxicity and enhanced drug concentration at the tumor site. Histological analysis confirmed reduced tumor cell proliferation and increased apoptosis. The findings suggest that polymer-based implants offer a promising strategy for improving therapeutic outcomes in glioblastoma by overcoming traditional delivery barriers and providing sustained drug exposure.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
